Table 1.
Clinical features of patients with nasopharyngeal carcinoma in the training set and validation set
| Characteristic | Training set | Validation set |
|---|---|---|
| n (%) | n (%) | |
| Total | 419 (100) | 309 (100) |
| Sex | ||
| Male | 393 (93.8) | 292 (94.5) |
| Female | 26 (6.2) | 17 (5.5) |
| Age (years) | ||
| <45 | 216 (51.6) | 165 (53.4) |
| ≥45 | 203 (48.4) | 144 (46.6) |
| Smoking | ||
| Yes | 113 (27.0) | 82 (26.5) |
| No | 306 (73.0) | 227 (73.5) |
| Stage (8th edition) | ||
| T2N0 | 77 (18.3) | 54 (17.5) |
| T1N1 | 198 (47.3) | 151 (48.9) |
| T2N1 | 144 (34.4) | 104 (33.6) |
| Lymph node site | ||
| Site1 | 94 (22.4) | 72 (23.3) |
| Site2 | 163 (38.9) | 117 (37.9) |
| Site3 | 162 (38.7) | 120 (38.8) |
| N category | ||
| N0 | 77 (18.3) | 54 (17.5) |
| N1 | 342 (81.7) | 255 (82.5) |
| Treatment | ||
| RT | 109 (26.0) | 80 (25.9) |
| CCRT | 310 (74.0) | 229 (74.1) |
| CT regimen | ||
| Triweekly | 257 (61.3) | 159 (51.5) |
| Weekly | 53 (12.7) | 70 (22.6) |
| NLR group | ||
| <2.8 | 263 (62.8) | 188 (60.8) |
| ≥2.8 | 156 (37.2) | 121 (39.2) |
| Fibrinogen (mg/mL) | ||
| <3.3 | 274 (65.4) | 203 (65.7) |
| ≥3.3 | 145 (34.6) | 106 (34.3) |
| EBV DNA (copies/mL) | ||
| <3000 | 237 (56.6) | 175 (56.6) |
| ≥3000 | 182 (43.4) | 134 (43.4) |
| Outcomes | ||
| Death | 24 | 20 |
| Distant metastasis | 20 | 14 |
| Localregional relapse | 6 | 5 |
Abbreviations: RT, radiotherapy; CCRT, concurrent chemoradiotherapy; CT, chemotherapy; NLR, neutrophil–lymphocyte ratio; EBV DNA, EBV (Epstein–Barr virus) DNA concentrations.